7 results
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
RIPE Therapy - Drug ... Microbiologically Confirmed Pulmonary ... Tuberculosis - ... #medications #pharmacology ... #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... Resistant Tuberculosis ... antimicrobials #regimens #pharmacology ... #dosing #idsa #
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... HIV-infected persons with clinical ... #TB #IDSA #Prevention ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
disease based on clinical ... Note: Active TB ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
Infection (Diffuse Pulmonary ... • Use until clinical ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology